Lamotrigine – An Update

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Volumn 23, Issue S2, 1996, Pages S6-S9

  Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

CONFERENCE PAPER; FOCAL EPILEPSY; HEADACHE; HUMAN; NAUSEA; PRIORITY JOURNAL;

ANTICONVULSANTS; EPILEPSY; HUMANS; TRIAZINES;

EID: 0029852003     PISSN: 03171671     EISSN: 20570155     Source Type: Journal    
DOI: 10.1017/S0317167100020904     Document Type: Article

References (48)

1. Reynolds EH, Milner G, Matthews AM, Chanarin I Anticonvulsant therapy, megaloblastic haemopoiesis and folic acid metabolism Quart J Med 1966; 35: 521-537.
2. Cohen AF, Land GS, Breimer DD et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-541.
3. Cociglio M, Alric R, Bouvier O. Performance analysis of a reversed-phase liquid chromatographic assay of lamotrigine in plasma using solvent-demixing extraction J Chromatogr 1991; 572: 269-276.
4. Sailstad JM, Findlay JWA. Immunofluorometric assay for lamotrigine (Lamictal) in human plasma. Ther Drug Monit 1991; 13: 433-442.
5. Fazio A, Artesi C, Russo M et al. A liquid chromatographic assay using a high-speed column for determination of lamotrigine, a new antiepileptic drug, in human plasma. Ther Drug Monit 1992; 14:509-512.
6. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: 2 neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-497.
7. McGeer EG, Zhu SG. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci Lett 1990; 112: 348-351.
8. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992; 13: 107-112.
9. Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type Ila Na+ channels with native Na+ channels in rat hippocampal neurones. Pflug Arch Eur J Physiol 1995; 430: 437-446.
10. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993; 612: 190-199.
11. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-176.
12. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharmaceut Med 1991; I: 121-128.
13. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW-430C) in healthy subjects with unconjugated hyperbilirubinaemia. Br J Clin Pharmac 1989; 28: 117-120.
14. Leach JP, Brodie MJ. Lamotrigine: clinical use. In: R Levy, RH Mattson, BS Meldrum, eds. Antiepileptic Drugs (4th edition). Raven Press, New York, USA, 1995, p 889-895.
15. Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomized double-blind, placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990; 56:221-226.
16. Jawad S, Richens A, Goodwin G, Yuen AWC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-363.
17. Smith D, Baker G, Davies G et al. A placebo-controlled, doubleblind, crossover trial of lamotrigine as add-on therapy on seizure frequency, severity, mood and quality of life in patients with treatment resistant epilepsy. J Neurol Neurosurg Psychiatry 1992;55:416-422.
18. Schapel GJ, Beran RE, Vajda FJE et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993; 56: 448-453.
19. Besag FMC. Lamotrigine in the management of subtle seizures. Rev Contemp Pharmacother 1994; 5: 123-131.
20. Pisani F, Xiao B, Fazio A et al. Single dose pharmacokinetics of carbamazepine-10,1 I epoxide in patients on lamotrigine monotherapy. Epilepsy Res 1994; 245-248.
21. Brodie MJ, Clifford JS, Yuen AWC and the Lamictal Study Group. Open multicentre trial of Lamictal (lamotrigine) in patients with treatment resistant epilepsy withdrawing from add-on to Lamictal monotherapy. Epilepsia 1994; 35 (suppl 7): 69-70.
22. Brodie MJ, Richens A, Yuen AWC and the UK Lamotrigine/ Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-479.
23. Steiner TJ, Silveira C, Yuen AWC and the North Thames Lamictal Study Group. Comparison of lamotrigine (Lamictal) and phenytoin in newly diagnosed epilepsy. Epilepsia 1994; 35 (suppl 7): 61.
24. Dulac O. The use of lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133-139.
25. Oiler LFV, Russi A, Oiler Daurella I. Lamotrigine in the Lennox-Gastaut syndrome. Epilepsia 1991; 32 (suppl I): 58.
26. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992; 32: 305-307.
27. Schlumberger E, Chavez F, Palacios L et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359-367.
28. Veggioti P, Cieuta C. Rey E, Dulac O. Lamotrigine in infantile spasms. Lancet 1994; 344: 1375-1376.
29. Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO. Interaction of lamotrigine with sodium valproate. Lancet 1993; 341: 445.
30. Ferrie CD, Panayiotopoulos CP. Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure 1994; 3: 157-159.
31. Pisani F, Di Perri R, Perucca E, Richens A. Interaction of lamotrigine with sodium valproate. Lancet 1993; 341: 1224.
32. Stolarek I, Blacklaw J, Forrest G, Brodie MJ. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994;57:921-924.
33. Brodie MJ. Lamotrigine. Lancet 1992; 339: 1397-1400.
34. Brodie MJ. Lamotrigine versus other antiepileptic drugs: a star rating system is born. Epilepsia 1994; 35 (suppl 5): S41-S46.
35. Yuen AWC, Bihari DJ. Multiorgan failure and disseminated intravascular coagulation in severe convulsive seizures. Lancet 1992; 340: 618.
36. Tavernor SJ, Wong ICK, Newton R, Brown SW. Rechallenge with lamotrigine after initial rash. Seizure 1995; 4: 67-71.
37. Chadwick DW, Shaw MDM, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentrations and the risk of drug-induced skin eruptions. J Neurol Neurosurg Psychiatry 1984; 47: 642-644.
38. Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 1991; 32 (suppl 2): S17-S2I.
39. Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. Br Med J 1995; 310: 504.
40. McKee PJW, Brodie MJ. Pharmacokinetic interactions with antiepileptic drugs. In: New anticonvulsants: advances in the treatment of epilepsy. Trimble MR, ed. John Wiley, Chichester, England, 1994: pi-33.
41. Depot M, Powell JR, Messenheimer JA, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990; 48: 346-355.
42. Brodie MJ. Drug interactions and epilepsy. Epilepsia 1992; 33 (suppl 1): S13-S22.
43. Brodie MJ. Drugs in focus: 10 Lamotrigine. Prescribes’ J 1993; 33:212-216.
44. Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy 1992;5:73-79.
45. Pisani F, Gallito G, Di Perri R. Could lamotrigine be useful in status epilepticus? A case report. J Neurol Neurosurg Psychiatry 1991;54:845-846.
46. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-443.
47. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect-toxicity relationships with lamotrigine-a prospective study. Epilepsia. 1996;37:534-538.
48. Leach JP, Brodie MJ. Novel antiepileptic drugs: an explosion of activity. Seizure 1995; 4: 5-17.